Effect of initial combination therapy vs. step-therapy on adherence and persistence in drug naïve type 2 diabetes...

Emerging evidence supports the early use of intensive combination treatments among type 2 diabetes (T2D) patients for rapid and sustained glycemic control. However, the impact of initial combination therapy on treatment adherence and persistence has not been explored. Therefore, we aimed to compare adherence and persistence to antidiabetic treatments between patients receiving initial combination therapy vs. conventional step-therapy.

A retrospective cohort study of MarketScan® research database (2017-2019) was conducted. We included drug naïve T2D patients who received step-therapy or initial combination therapy and were continuously enrolled in Commercial, Medicare, or Medicaid health plans during the pre-index and follow-up period. Primary outcomes of interest were antidiabetic treatment adherence and persistence during the first year of treatment initiation.

In the Commercial/Medicare population, out of the total 116,597 patients, 52 % were nonadherent and 58 % were nonpersistent. Similarly, in the Medicaid population of 18,295 patients, 63 % were nonadherent and 67 % were nonpersistent. Patients receiving step-therapy were more likely to be adherent compared to the initial combination group in both populations (Commercial/Medicare: OR 1.52, 95 % CI 1.46-1.57; Medicaid: OR 1.24, 95 % CI 1.11-1.38). Additionally, in the Commercial/Medicare population, the multivariable Cox regression model showed that the step-therapy cohort had a significantly lower hazard for time to non-persistence compared to the initial combination cohort (HR 0.9, 95 % CI 0.86-0.94). However, this was not significantly different in the Medicaid population.

This study suggests that step-therapy as an initial pharmacotherapy approach may be associated with improved adherence and persistence in managing diabetes compared to initial combination therapy.